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ABSTRACT 
Aims 
The objective of this study was to investigate the effect of a berberine derivative, 
berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the 
mechanisms involved. 
Methods 
Lipid lowering effect of berberine and berberine8998 was determined by high fat diet 
model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were 
analyzed. The potential target proteins on hamster liver were screened by iTRAQ 
labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and 
ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to 
demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 
8998 was conducted on SD rats. 
Results 
Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c 
levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared 
similar metabolic pathways where fatty acid metabolism was the most dominant one. 
Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 
(ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty 
acid metabolism, expressed differently in berberine8998 group comparing with both 
model group and berberine treatment group. Further biochemistry results showed that 
berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may 
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lead to the reduction of TG levels in berberine8998 treatment groups and the 
difference in proteomics. Pharmacokinetic study showed that berberine8998, could 
remarkably improve absorption by 6.7 times, comparing with berberine. 
Conclusion 
These findings suggest that berberine8998 lowers both cholesterol and lipid with 
different mechanisms from berberine and is a promising therapeutic candidate for 
treating hypercholesterolemia and obesity. 
Keywords: Berberine8998, Proteomics, Lipid-lowering, Fatty acids. 
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Introduction 
Berberine is an isoquinoline alkaloid (Fig. 1A) and the main active constituent of 
Coptis deltoids[1]. In traditional Chinese medicine, berberine-containing herbs are 
used to treat various conditions and diseases, including diarrhea, cancer, depression, 
hypertension, hypercholesterolemia, and diabetes mellitus[2]. It has also been shown to 
have significant lipid-lowering activity. Treatment of hypercholesterolemic patients 
with orally administered berberine reduced serum levels of cholesterol, and 
low-density lipoprotein (LDL) by 29% and 25%, respectively; in hyperlipidemic 
hamsters, berberine treatment reduced serum total cholesterol (TC) by 40% and LDL 
by 42%[3]. 
However, the effect of berberine on triglycerides (TG) and its associated mechanisms 
were not fully understood. Serum TG concentrations and risk for coronary heart 
disease has been an issue of great interest [4]. Fatty acids (FAs) are important 
metabolic substrates for energy production. Excess FAs and unesterified cholesterol 
are stored in lipid droplets within triacylglycerol (TG)[5]. 
LDL is a major risk factor for atherosclerosis and coronary heart disease[6, 7] and is the 
main target of lipid-lowering drugs[8]. Berberine increases the abundance of LDL 
receptor (LDLR) [3] in the liver by stabilizing its transcript[9]. Upregulating LDLR 
expression on the hepatocyte surface by genetic or pharmacologic means has been 
shown to increase hepatic clearance and reduce serum levels of LDL-cholesterol[10-12]. 
LDLR activity is therefore considered as a key factor determining LDL-cholesterol 
concentration in the systemic circulation. 
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Berberine and its derivatives have multiple mechanisms involved in its lipid lowering 
effect. Berberine reduced serum LDL-c by inducing LDLR expression in liver. 
Signaling pathway studies showed that berberine activated AMPK, ERK and other 
pathways. Berberine also up-regulated liver X receptor a (LXRα), peroxisome 
proliferator-activated receptor α/δ (PPARα/δ) expression and down-regulated PPARγ 
expression in the liver[13].
The isobaric tags for relative and absolute quantitation (iTRAQ) method combined 
with 2D LC-MS/MS is one of the most powerful methodologies in quantitative 
proteomics which has been applied and reviewed in a variety of reports[14, 15]. 
Proteomics has been showing a great potential in mechanism research. The advent of 
proteomics analysis has permitted effective expression measurement of large set of 
samples. Therefore, proteomics may applied to analyze the mechanisms of lipid 
lowering effect of berberine. 
Another obstacle for application of berberine in the treatment of hypercholesterolemia 
was its low bioavailablity. The oral dose of berberine is typically 1.0 g/day (10 
pills/day) which limited its clinical application[16]. Therefore, screening of berberine 
derivatives will facilitate the improvement of its bioavailability. 
In this study, a newly synthesized berberine derivative, berberine8998 (Fig. 1B) was 
well characterized. In-vivo study showed that berberine8998 significant lowered the 
total cholesterol, low-density-lipoprotein and triglycerides levels in hamsters while 
berberine only lowered total cholesterol and triglycerides. In-depth iTRAQ 
proteomics unveiled that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and
Acta Pharmacologica Sinica
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long-chain-fatty-acid—CoA ligase 1 (ACSL1), a protein involved in fatty acid 
metabolism, expressed differently in berberine8998 group comparing with both model 
group and berberine treatment group. Mechanistic study showed that berberine8998 
significantly lowered the non-esterified fatty acid (NEFA), which may lead to the 
reduction of TG levels in berberine8998 treatment groups.Further pharmacokinetic 
study showed that berberine8998, could remarkably improve absorption by 7.74 times, 
comparing with berberine. These findings suggest that berberine8998 lowers both 
cholesterol and lipid with different mechanisms from berberine and is a promising 
therapeutic candidate for treating hypercholesterolemia and obesity. 
Materials and methods 
Chemical and reagents 
Berberine (purity >98%) was purchased from Northeast Pharm (China). 
Berberine8998 
(purity >97%) was synthesized by Youhong Hu (Shanghai Institute of Materia 
Medica, 
Shanghai, China). Dulbecco’s modified Eagle’s medium (DMEM) was purchased 
from HyClone Laboratories (Logan, Utah, USA). Fetal bovine serum (FBS) was 
obtained from ThermoFisher Scientific (Carlsbad, California, USA). Provastatin was 
purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Non-esterified fatty acids 
Animals and procedures 
Hamsters, clean class at 6 weeks of age, were obtained from the Animal Center of 
Shanghai Institute of Materia Medica. Hamsters were randomly divided into four 
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groups (normal diet, model, berberine, berberine8998 groups). Berberine and 
berberine8998 were dissolved in CMC-Na before administered. Hamsters on the 
normal diet received carboxymethylcellulose sodium (CMC-Na) as the negative 
control group (n=3). Hamsters on a high-fat diet (HFD) (0.15% cholesterol and 18% 
fat) were administered CMC-Na, berberine or berberine8998 (50 mg/kg, as berberine 
and berberine8998 respectively, n=12) daily in an intragastric manner for 3 weeks. 
Body weight was monitored. 
At the every week in the treatment period (7, 14 and 21 days post-dose), all hamsters 
were fasted overnight (12 h) and blood samples, anti-coagulated with 3.8% sodium 
citrate (w/v), were drawn from the retro-orbital plexus. Blood samples (0.3–0.5 mL) 
were collected weekly from the orbits after a 16 h fasting, and centrifuged for 15 min 
at 3000 × g to obtain serum. Serum lipid profiles, including total cholesterol (TC), 
LDL cholesterol (LDL-C) and triglyceride (TG) levels, were measured using an 
automatic analyzer (Hitachi, Tokyo, Japan). 
The animal experiments were conducted according to the National Research Council’s 
Guidelines. All experimental protocols and procedures were approved by the Institutional 
Ethical Committee of Shanghai Institute of Materia Medica. 
Protein extraction and iTRAQ reagent labeling 
To determine the protein expression differences in berberine and berberine8998 
treatment groups, livers of hamsters from different treatment groups were collected, 
snap-frozen in liquid nitrogen, and stored at -80°C. The samples were dissolved in 
lysis buffer composed of 7 M urea, 2 M thiourea, 65 mM dithiothreitol, and 0.1 mM 
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phenylmethylsulfonyl fluoride at 4°C, and sonicated three times at 70 W for 5 s at 10 
s intervals, followed by three rounds of homogenization using a whirlpool mixer at 10 
min intervals. Samples were centrifuged at 20000g for 30 min at 4°C and the protein 
concentration in the supernatant was determined by the Bradford assay, with BSA 
used to generate the calibration curve. 
Trypsin digestion and iTRAQ labeling were carried out. Liver proteins (150 µg) from 
each hamster were reduced and alkylated and then digested overnight at 37°C with 
trypsin (MS grade; Promega, Fitchburg, WI, USA). Samples were labeled with 
iTRAQ reagent (Applied Biosystems) as follows: berberine, iTRAQ reagent 113/114; 
berberine8998, reagent 115/116; and control, reagent 117/118. Two sets of six 
isobaric tags were applied to the 12 digested protein samples. 
Two-dimensional LC-MS/MS analysis based on Triple TOF 5600 
Mixed peptides were fractionated by strong cation exchange chromatography on a 
20AD high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, 
Japan) using an polysulfoethyl column (Nest Group, Southborough, MA, USA) with 
the following dimensions: 2.1 × 100 mm, 5 µm, and 300 Å. Mixed peptides were 
desalted with a Sep-Pak Cartridge (Waters, Milford, MA, USA), diluted with loading 
buffer (10 mM KH2PO4 in 5% acetonitrile [ACN], pH 2.8), and loaded onto the 
column. Buffer A was identical in composition to the loading buffer. Buffer B was the 
same as Buffer A except that it contained 350 mM KCl. Peptide separation was 
carried out using a linear binary gradient of 0%–50% Buffer B in Buffer A at a flow 
rate of 200 µL/min for 1 h. Absorbance at 214 and 280 nm was monitored, and 30 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9 
strong cation exchange fractions were collected along the gradient, dried, dissolved in 
Buffer C (5% ACN and 0.1% formic acid [FA]), and analyzed on a Triple TOF 5600 
mass spectrometer (Applied Biosystems). Peptides were separated on a Zorbax 
300SB-C18 reversed-phase column (Agilent Technologies, Santa Clara, CA, USA) 
with the following dimensions: 0.1 × 15 mm, 5 µm, and 300 Å with a gradient of 5%–
35% Buffer D (95% ACN and 0.1% FA) in Buffer C at a flow rate of 0.2 µL/min for 
65 min. Survey scans were acquired from m/z 400 to 1800, with ≤ 10 precursors 
selected for MS/MS from m/z 100–2000 using a dynamic exclusion of 30 S for 
selected ions. The iTRAQ-labeled peptides were fragmented under collision-induced 
dissociation conditions to yield reporter ions at 113.1, 114.1, 115.1, 116.1, 117.1, and 
118.1; the ratios of their peak areas reflected the relative abundance of the peptides 
and therefore of the proteins in the samples. Larger sequence information-rich 
fragment ions were also produced under the same MS/MS conditions and provided 
the identity of the protein from which the peptide originated. 
Bioinformatic analysis 
Protein Pilot v4.5 (Applied Biosystems) was used to identify and quantify 
iTRAQ-labeled peptides. This software was also used to determine the minimum 
number of identified peptides by removing redundant hits. MS/MS data were 
searched with UniProt. The rat database was used since the hamster database was not 
available. The precursor and iTRAQ fragment tolerance values were set to 100 ppm 
and 0.6 Da. Parameters for data analysis were: sample type = iTRAQ 
(peptide-labeled); Cys alkylation = methyl methanethiosulfonate; digestion = trypsin; 
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instrument = time-of-flight 5600 ESI; species = RAT; ID focus = biological 
modifications; database = Swissprot Rat (35672 entries). 
To minimize the occurrence of false positive results, a decoy database search strategy 
was adopted to estimate the FDR < 1% for peptide and protein identification. At least 
one peptide with a confidence interval of 95% was included. Data were considered 
reliable for P < 0.05 and error factor < 2. The P value from the Student’s t test was 
used to evaluate the significance of the change in protein expression level. 
Fold-change ratios < 0.7 (downregulated) or > 1.3 (upregulated) were selected as 
cutoff values. Gene Ontology (GO) analysis (http://www.geneontology.org/) was used 
to verify the function of proteins that were up- or downregulated by berberine or 
berberine8998 treatment. The signaling pathways of proteins were identified by 
searching the Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
(http://www.genome.jp/kegg/ pathway.html). MATLAB (MathWorks, Natick, MA, 
USA) was used for mathematical modeling and for analyzing KEGG pathways. 
Western blotting of the candidate protein 
Liver tissue lysates (20 µg) were resolved by 8% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene 
difluoride membranes (0.22 µm) using a semi-dry transfer system (Bio-Rad, Hercules, 
CA, USA). Membranes were blocked with 5% BSA in buffer composed of 20 mM 
Tris-HCl, 150 mM NaCl, and 0.1% Tween 20 at room temperature for 2 h. 
Membranes were incubated with mouse monoclonal antibodies against LDLR (1:2000) 
and ACOX1 (1:200) (both from Abcam, Cambridge, UK) at 4°C overnight. After 
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washing, membranes were incubated with anti-mouse IgG (1:2000; Bio-Rad) at room 
temperature for 2 h, followed by detection with a Clarity Enhanced 
Chemiluminescence Western Blot Substrate kit (Bio-Rad). Densitometry was carried 
out using Quantity One software (Bio-Rad). The ratio of gray values of target proteins 
represented the relative expression levels for each group. The experiment was 
repeated three times. 
Measurement of NEFA levels 
Serum samples from 60 hamsters were divided into berberine- and 
berberine8998-treated and untreated control groups (n =20 each). NEFA levels were 
determined by an assay that measures the conversion of fatty acids to acyl-CoA in the 
presence of acyl-CoA synthetase. Acyl-CoA is oxidized by addition of acyl-CoA 
oxidase, which generates hydrogen peroxide, which in turn causes oxidative 
condensation of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline with 4-aminoantipyrine 
in the presence of peroxidase to yield a product whose absorbance was measured at 
550 nm with the Automatic Biochemical Analyzer. The NEFA-HA Test kit (Wako, 
Japan) was used for this measurement. 
Measurement of DiI-LDL uptake by HepG2 cell LDLRs 
HepG2 cells were maintained in Dulbecco’s modified Eagles' medium (DMEM)
(Hyclone) containing 10% (v/v) fetal bovine serum (FBS). Cells were incubated under 
a humidified atmosphere of 95% O2 and 5% CO2 at 37 °C at a density of 106 cells 
per mL. HepG2 cells were incubated with DiI-LDL (Biotium, Hayward, CA, USA) 
and the following test compounds: pravastatin (positive control, 5 µM) (Sinopharm, 
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Shanghai, China), berberine (40 µM), or berberine8998 (20 or 40 µM). DiI-LDL 
uptake was determined as follows. The culture medium was removed, and plates were 
washed three times with 0.4% BSA in phosphate-buffered saline. Isopropanol (0.5 
ml/well) was then applied to extract DiI-LDL from the cells. A 200 µL volume of 
supernatant was transferred to a black fluorescent screen to determine DiI-LDL 
absorption at excitation/emission wavelengths of 520/570 nm. Total DiI-LDL uptake 
was determined at 37°C using a SpectraMax M2e fluorescence detector (Molecular 
Devices, Silicon Valley, CA, USA). Hepatic hydrogen peroxide level was measured 
by a hydrogen peroxide testing kit (Beyotime Biotech., Haimen, China). Hepatic 
lipoperoxide level was tested using a malondialdehyde (MDA) testing kit (Nanjing 
Jiancheng Biotech., Nanjing, China). 
Pharmacokinetic study of berberine8998 
Male Sprague-Dawley (SD) rats (clean class, 180-200g, n=10, provided by the 
Animal Center of Shanghai Institute of Materia Medica) were randomly divided into 
two groups. After twelve hours of food deprivation, rats were administered 
berberine and berberine8998 (50 mg/kg, free base) intragastrically (i.g). The washout 
interval between two treatment periods was 7 days after the final blood collection. 
After the washout period, rats were given the alternating compound in the second 
period. Sample collection protocol was identical in two treatment periods. Blood 
samples (0.5 mL) were collected pre-dose and at 0.5 h, 1 h, 2 h, 3 h, 5 h, 6 h, 7 h, 8 h, 
12 h, 24 h, and 48 h after dosing in each treatment period. The collected blood 
samples were centrifuged at 3000 g for 15 min at 4°C within 30 min of the 
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collection time. Serum samples were fractionated by chromatography on a 20AD 
high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan) 
using an reverse phase column (CAPCELL PAK C18, 2.0perfor，5hromatogratical 
data was processed by Phoenix® WinNonlin® 6.3 to calculate pharmacokinetics 
parameters. 
Similar procedures were adopted in Syrian hamsters. Syrian hamsters (clean class, 
90~120g, n=6, provided by the Animal Center of Shanghai Institute of Materia 
Medica) were randomly divided into two groups. After twelve hours of food 
deprivation, hamsters were administered berberine and berberine8998 (50 mg/kg, free 
base) intragastrically (i.g). Blood samples (0.5 mL) were collected pre-dose and at 0.5 
h, 1.5 h, 3 h, 6 h, 8 h after dosing in each treatment period. 
Results 
Berberine8998 ameliorates high fat diet induced hypercholesterolemia in 
hamsters 
We initially evaluated the effects of berberine8998 on lipid levels in vivo. 
Six-week-old male hamsters on a high fat diet were randomized to receive berberine 
(50mg/kg/d), berberine8998 (50mg/kg/d) or CMC-Na for 3 weeks. Hamsters on chow 
diet were administered CMC-Na as the normal diet control group. Serum lipid levels 
including (total cholesterol, low density lipoprotein cholesterol, triglyceride and high 
density lipoprotein cholesterol) was analyzed every week. 
Hypercholesterolemia was developed slowly in the normal diet group (Figure 2A-2C) 
while serum lipid levels in the high fat diet (HFD) model group were significantly 
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increased (Figure 2A-2C). Notably, berberine8998 treatment (50 mg/kg/d) 
significantly reduced total cholesterol (Figure 2A) and LDL-c (Figure 2B) on week 2 
and week 3, compared with the HFD group (P< 0.05). In particular, berberine did not 
alter the LDL-c levels in three weeks treatment (Figure 2B) while berberine8998 
attenuated LDL-c levels on week 2 and week 3 (P<0.05). Mean levels of week 2 and 
week 3 were 10.30±3.63 and 13.15±7.34  (nM, Mean± SD)for HFD and 6.00±1.85, 
8.55±2.59 (nM, Mean± SD) for berberine8998 (50mg/kg) groups, respectively 
(Figure 2B). 
Given that triglyceride (TG) is an important component of lipid, the serum TG levels 
in hamsters was evaluated with bio-chemistry analyzer. TG levels had similar changes 
to TC and LDL-c. The results showed that berberine8998 ameliorated the elevated 
serum TG levels induced by high fat diet. TG was decreased by 64% after using 
berberine8998 (Fig. 2C). Triglyceride levels were significantly attenuated on week 3 
in both berberine (P< 0.05) and berberine8998 groups (P< 0.01) (Figure 2C). Body 
weight was not significantly different among treatment groups, model and normal diet 
groups as shown in Figure 2D. 
GO analysis indicates similar cellular locations in berberine and berberine8998 
treatment group 
Hamster liver samples from the berbreine, berberine8998 and high fat diet model 
groups were analyzed by iTRAQ shot-gun proteomics. High-abundant proteins were 
depleted before the analysis. A total of 2049 and 2020 proteins were identified by the 
first and second iTRAQ experiments, respectively, with a false discovery rate lower 
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15 
than 1%. Upon combing results of the two replicates, a total of 2444 proteins were 
identified and 2073 proteins were quantified. 
In order to elucidate the location and function of these proteins, gene ontology 
analysis and KEGG analysis were conducted. The analysis of cellular component by 
GO analysis revealed that proteins were located in the similar cellular components in 
high fat diet group, berberine treatment group and berberine8998 group. The top five 
enriched cellular component was cell part, organelle part, organelle, macromolecular 
complex and membrane-enclosed lumen. The top five molecular function included 
binding, catalytic activity, structural molecule activity, transporter activity and 
enzyme regulator activity (Figure 3A). 
KEGG analysis indicates similar metabolic pathways in berberine and 
berberine8998 treatment group 
A total of 442 differentially expressed proteins were screened in both runs in 
berberine8998 group and a total of 268 differentially expressed proteins were 
screened in both runs in berberine group. In order to filter the non-significant changes 
in  liver protein expression level between sample groups, fold change in median 
ratios < 0.7 (down-regulated) or > 1.3 (upregulated) were selected as cutoff values 
and the ratio was assessed with the Student’s t test and the median value of the ratio 
between two groups was also calculated. In berberine8998 group, a total of 48 
proteins were determined as significant changes, were 16 upregulated, and 32 were 
downregulated. In berberine group, a total of 53 proteins were determined as 
significant changes, 23 were upregulated (Table 2), and 30 were downregulated. The 
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top ten of the most significant changes in protein expression after berbrine8998 and 
berbrerine treatment were summarized in Table 1 and Table 2. 
KEGG metabolic pathways were analyzed to determine the major pathways involved 
in berberine and berberine8998 treatment. P values were determined for pathways 
represented in the treatment groups (berberine- and berberine8998 treatment groups). 
As shown in Figure 3B, the major KEGG pathways were fatty acid metabolism, 
ribosome, pyruvate metabolism, propanoate metabolism and butanoate metabolism. 
The most significantly metabolic pathway was fatty acid metabolism. These results 
suggested that berberine8998 and berberine lowered the serum lipids through similar 
metabolic pathways. 
Fatty acid metabolism is the major pathway affected by berberine8998 
Although the major metabolic pathways were similar in berberine and berberine 8998 
treatment groups, the differences in the magnitude of the target proteins were 
examined. According to bioinformatics analysis, fatty acid metabolism was the most 
significant pathway involved in the lipid lowering effects. Therefore, we selected two 
of the differentially expressed proteins, ACOX1 and ACSL1, for validation by 
western blotting. ACOX1 and ACSL1expression in the liver was down regulated in 
berberine and berberine8998 treatment groups as compared to the control group (Fig. 
4A). The protein expression of ACOX1 and ACSL1 significantly decreased by 
berberine 8998 treatment by approximately 2~3 fold. The protein expression of 
ACOX1 and ACSL1 significantly decreased by berberine treatment by approximately 
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1~2 fold. Therefore, the magnitude of ACOX1 and ACSL1 protein expression varied 
in berberine and berberine8998 treatment groups. 
ACOX1 involves in the β-oxidation of fatty acid metabolism. Given to the reduction 
of TG levels in vivo (Figure 2C), serum non-estified fatty acid levels were analyzed. 
Serum NEFA levels exhibited similar changes (4.07 vs. 4.93 mmol/L; P < 0.05; Fig. 
4B) when compared with high fat diet group. These results suggest that berberine8998 
reverses the increase in serum TG and NEFA levels induced by a high-fat diet. 
To further unveil the associated mechanisms of lowering serum LDL levels with 
berberine8998, a Dil-LDL uptake experiment was conducted in HepG2 cells. 
Berberine8998 (40 µM, 2.26) dose-dependently stimulated in LDL uptake in HepG2 
cells comparing with berberine (2.26 vs 1.22 P<0.01) (Fig. 4C). Since the 
LDL-uptake is mediated by LDL receptor in HepG2 cell, we evaluated LDLR 
expression in HepG2 cells by western blotting. As shown in Fig 4D, LDLR was 
upregulated dose-dependently by treatment with berberine and berberine8998, with 
the latter inducing a greater effect. These results further confirm that berberine8998 
promotes the uptake of LDL by increasing the expression of LDLR. 
To unveil the mechanisms involved in the effect of ACOX1 on fatty acid metabolism. 
Hepat ic malondialdehyde (MDA) and peroxide levels were analyzed. Besides, 
mitochondrial fatty acid oxidation was analyzed by PGC-1α and UCP-1 expression. 
The results showed that hepatic malondialdehyde (MDA) and peroxide levels was 
inhibited though not significant. The RNA levels of PGC-1 α and UCP-1 expression 
were increased through treatment (Figure 4E, 4F and 4G). 
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Berberine8998 significantly improved bioavailability in SD rats and hamsters
The pharmacokinetics of berberine8998 and berberine was further evaluated in SD rat. 
The mean serum concentration versus time profile was presented in Fig. 5. The 
principal pharmacokinetic parameters of berberine and berberine8998 are summarized 
in Table 3.  The maximum concentration of berberine and berberine8998 in serum 
(Cmax) was 55.11ng/mL and 230.3ng/mL. The half-life of berberine and 
berberine8998 in serum (t1/2) was 29.18 h and 10.97 h. The area under curve (AUC0-48) 
was 312.4 ng/mL·h and 2418 ng/mL·h for berberine and berberine8998, respectively. 
These results suggested that the bioavailablity of berberine was significantly 
improved by 6.7 times in SD rats. 
Similar results were also observed in hamsters. As shown in Figure 5B and Table 4. 
The bioavailablity of berberine was significantly improved by 3.6 times in hamsters. 
Discussion 
In this research, proteomes profiles of high fat hamster liver tissues samples with or 
without berberine8998 were simultaneously compared. It was the first time that 
iTRAQ method was coupled with 2D LC-MS/MS (TripleTOF 5600) to investigate the 
mechanisms of how berberine and berberine8998 produce their action. Two 
differentially expressed proteins (ACOX1 and ACSL1) identified by the proteomics 
approach were further selectively validated using western blotting and biochemical 
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analysis. The protein expression differences may be result from the improvement of 
bioavailability of berberine8998 
The results of berberine8998 on serum lipids were determined for the first time and 
was compared with berberine. The results in Figure 2 illustrated a significant 
reduction in LDL, total TC and TG levels while berberine took effect on TC and TG, 
with a weaker extent.  In order to elucidate the possible mechanisms involved in this 
improvement, the function, the interplay and the changes in abundance of proteins are 
in response to internal and external cues[15]. The iTRAQ method combined with 
two-dimensional LC–MS/MS was used to analyze protein expression in the liver 
tissue of mice maintained on a high-fat diet treated with berberine or berberine8998. 
Previous studies investigated the proteomic effects of berberine on multi-target 
antimicrobial[13] and breast cancer cells[17]. The proteomic profiles of berberine8998 
treatment on hamsters were remained unknown. This is among the most powerful 
methodologies in quantitative proteomics[18]. Using the iTRAQ method, in 
berberine8998 group, a total of 48 proteins were determined as significant changes, 
were 16 upregulated, and 32 were downregulated. In berberine group, a total of 53 
proteins were determined as significant changes, 23were upregulated, and 30 were 
downregulated. 
The GO analysis showed that proteins that were differentially expressed in the 
treatment relative to the control group had similar cellular locations; the KEGG 
pathway enrichment suggested that fatty acid metabolism were specifically activated 
by the treatment. The hepatic ACOX1 expression was significantly lower in 
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berberine8998 group. Western blotting assay results confirmed 
berberine8998-induced change in levels of ACOX1 and other related proteins. These 
results suggested that berberine8998 could reduce serum NEFA levels by modulating 
ACOX1 expression. With iTRAQ proteomics, the effect of berberine8998 on TG was 
mediated by NEFA and hepatic ACOX1 expression. NEFA was down-regulated by 
berberine8998. This ACOX1-regulated mechanism suppresses the in-vivo TG and 
NEFA levels, which is a newly defined mechanism of berberine8998 in its lipid 
lowering effect. Further mechanism studies revealed that berberine8998 enhanced 
hepatic LDL uptake by increasing LDLR expression. Consistent with the lipid 
lowering effect, berberine8998 up-regulated bio-availability in SD rats comparing 
with berberine, and the mechanisms involved may require further investigations. 
The reduction of total cholesterol and LDL were observed in both berberine and 
berberine8998. The mechanisms of cholesterol lowering by berberine8998 were 
similar with that of berberine. The uptake of LDL in HepG2 cells and the 
upregulation of LDLR expression were observed in both berberine 8998 and 
berberine treatment groups. Consistent with these findings, we found that berberine 
and to a greater extent, berberine8998 stimulated the uptake of LDL in HepG2 cells, 
which is similar to the cholesterol-lowering agent pravastatin. The intensity (a.u.) of 
Dil-LDL in HepG2 cells was screened to compare the lipid uptake amount of positive 
control group (Pravastatin), berberine group and berberine8998 group. The western 
blot analysis showed that the upregulation of LDLR expression was greater in cells 
treated with berberine8998 as compared to berberine, indicating that berberine8998 
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has superior lipid-lowering effects to the parent molecule in vitro. As shown in Figure 
4E-4G, hepatic malondialdehyde (MDA) and peroxide levels was inhibited though 
not significant. The RNA levels of PGC-1 α and UCP-1 expression were increased 
through treatment (Figure 4E, 4F and 4G). The inhibition ACOX1 was reported to 
improve hepatic lipid and reactive oxygen species metabolism[13], which was similar
in this study. Therefore, inhibition of ACOX1 involved in the lipid lowering effects of 
berberine8998. 
Berberine derivative berberine8998 could greatly improve the absorption of berberine 
by 7.74 times (AUC0-48 of berberine8998 / AUC0-48 of berberine). High availability of 
berberine8998 contributed at least in part of its lipid lowering efficacy. The 
mechanisms of absorption improving effect of berberine8998 will be explored in 
future. 
In conclusion, berberine8998 significantly lowered LDL, total cholesterol levels in 
hamsters via upregulation of hepatic LDLR expression. The reduction of TG levels in 
berberine 8998 treated hamsters was associated with lower NEFA levels. The iTRAQ 
proteomic studies revealed that ACOX1 was significantly inhibited in berberine8998 
treatment group. The effect of berberine8998 on TG was mediated by NEFA and 
hepatic ACOX1 expression. This ACOX1-regulated mechanism suppresses the 
in-vivo TG and NEFA levels, which is a newly defined mechanism of berberine8998 
in its lipid lowering effect. The improvement of bioavailability in berberine8998 will 
be explored in the future. 
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Tables 
Table 1. List of differentially expressed proteins after berberine88998 treatment in hamsters. 
The proteins were identified by TOF-AB 5600. (↑, up-regulated; ↓, down-regulated). 
Table 2. List  of differentially expressed proteins after berberine treatment  in hamsters. The 
proteins were identified by TOF-AB 5600. (↑, up-regulated; ↓, down-regulated). 
Table 3. Pharmacokinetic parameters of berberine and berberine8998 in SD rats. 
Table 4. Pharmacokinetic parameters of berberine and berberine8998 in hamsters. 
Figure legends 
Figure 1. Chemical structures of (A) berberine and (B) berberine8998. 
Figure 2. Analysis of (A) LDL and serum (B) TC and (C) TG levels in hamsters 
treated with berberine or berberine8998 or left untreated over 3 weeks. (*P<0.05, 
**P<0.01 compared with high fat diet group). 
Figure 3. (A) GO analysis of cellular components (B) biological processes associated 
with differentially expressed proteins in BBR (berberine- reated) and BBR-8998 
(berberine8998- reated) hamsters.  
Figure 4. (A) Western blot analysis of ACOX1 expression in hamsters treated with 
BBR (berberine) or berberine8998 (BBR-8998) vs. untreated controls fed a high-fat 
diet. All results are from four independent experiments. (B) Serum levels of NEFAs. 
Hamsters were maintained on a normal or high-fat diet. In high fat diet hamsters, one 
group received no treatment, while the other two groups were treated with berberine 
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or berberine8998 (50 mg/kg each). (C) Average uptake amount of Dil-LDL in HepG2 
cell incubated with test compounds. Pro, pravastatin; Berberine; Berberine8998. (D) 
Western blot analysis of LDLR expression level. Neg (blank); POS, (pravastatin 
5uM); BBR (Berberine 2uM and 10uM); 8998 (Berberine8998 2uM and 10uM). (E) 
MDA levels. (F) Peroxide levels (G) Hepatic RNA expression of PGC-1α and UCP-1. 
All results are from three independent experiments. 
Figure 5. The mean concentration–time profile following a single oral administration 
of 70 mg/kg berberine and berberine8998 to SD rats 
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